4VI Stock Overview

Researches, develops, manufactures, and commercializes innovative molecular diagnostic products in optical systems and isothermal nucleic acid amplification methods in Poland and internationally. More details

4VI fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Earnings have grown 0.2% per year over the past 5 years

Risk Analysis

Makes less than USD$1m in revenue (PLN1,000)

Has less than 1 year of cash runway

Shareholders have been diluted in the past year

Does not have a meaningful market cap (€106M)

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Genomtec S.A. Competitors

4SC

DB:VSC

€43.7m

Medigene

XTRA:MDG1

€15.2m

co.don

XTRA:CNW

€6.5m

Heidelberg Pharma

XTRA:HPHA

€105.8m

Price History & Performance

Summary of share price highs, lows and changes for Genomtec
Historical stock prices
Current Share Price	zł1.67
52 Week High	zł3.35
52 Week Low	zł1.38
Beta	0.25
1 Month Change	13.90%
3 Month Change	6.23%
1 Year Change	-24.34%
3 Year Change	-12.23%
5 Year Change	n/a
Change since IPO	-35.57%

Recent updates

Shareholder Returns

	4VI	DE Biotechs	DE Market
7D	4.9%	-2.9%	-2.6%
1Y	-24.3%	-14.7%	6.9%

Return vs Industry: 4VI underperformed the German Biotechs industry which returned -14.7% over the past year.

Return vs Market: 4VI underperformed the German Market which returned 6.9% over the past year.

Price Volatility

Is 4VI's price volatile compared to industry and market?
4VI volatility
4VI Average Weekly Movement	9.5%
Biotechs Industry Average Movement	6.8%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.2%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 4VI's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 4VI's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2016	17	Miron Tokarski	www.genomtec.com

Genomtec S.A. researches, develops, manufactures, and commercializes innovative molecular diagnostic products in optical systems and isothermal nucleic acid amplification methods in Poland and internationally. The company develops Genomtec ID, a technological device that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analyzing the biological material of patients using swabs, urine samples, saliva, blood, and other body fluids. It also develops Genomtec Tumor, a SNAAT based solution used to identify neoplastic mutations and mutations with prognostic value in neoplastic disease; Genomtec SARS-CoV-2 EvaGreen and Direct-RT-LAMP CE-IVD Kit to detect SARS-CoV-2 RNA in various biological samples from patients with suspected COVID-19 infection; and Genomtec RT-LAMP CE-IVD Duo-Kit for the detection of all variants of the SARS-CoV-2 virus.

Genomtec S.A. Fundamentals Summary

How do Genomtec's earnings and revenue compare to its market cap?
4VI fundamental statistics
Market cap	€24.85m
Earnings (TTM)	-€2.72m
Revenue (TTM)	€234.61

Over9,999x

P/S Ratio

-9.2x

P/E Ratio

Is 4VI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4VI income statement (TTM)
Revenue	zł1.00k
Cost of Revenue	zł2.63m
Gross Profit	-zł2.63m
Other Expenses	zł8.95m
Earnings	-zł11.58m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.87
Gross Margin	-263,000.00%
Net Profit Margin	-1,157,600.00%
Debt/Equity Ratio	4.3%

How did 4VI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 01:00
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genomtec S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution